The EMAs Committee for Medicinal Products for Veterinary Use (CVMP) has unanimously appointed David Murphy from Ireland as its new Chair for the next three years. Murphy, a qualified veterinarian, is the Veterinary Assessment Manager at the Health Products Regulatory Authority in Ireland.
Designed to investigate the effects of strain or pressure to 2D and 3D cell cultures or the effects of fluid shear stress to 2D cultures, the Flexcell equipment offers its users various possibilities to set their cells under stress.
Amgens Imlygic was approved last year – a move that finally added oncolytic viruses (OVs) to the healthcare toolkit. Although the treatments scope of application as a stand-alone therapy is limited, many are viewing the event as Ground Zero for an explosive new age in medicine. Evidence is mounting that the full potential of virotherapies can only be realised in combination with other immunotherapies, chemotherapies or small-molecule therapies. A number of other European drug developers have now jumped on Amgens bandwagon.
Torsten Hombeck will take charge of the commercial activities and the general strategy of Promethera Biosciences. The Belgian cell therapy specialist appointed Hombeck as Chief Commercial and Strategy Officer.